Omnicell (NASDAQ:OMCL) Given New $158.00 Price Target at Wells Fargo & Company

Omnicell (NASDAQ:OMCL – Get Rating) had its price objective lowered by equities research analysts at Wells Fargo & Company from $188.00 to $158.00 in a research note issued on Tuesday, The Fly reports. Wells Fargo & Company‘s price target suggests a potential upside of 37.51% from the company’s current price.

A number of other research firms also recently weighed in on OMCL. Piper Sandler cut their price target on Omnicell from $181.00 to $162.00 in a research note on Monday. StockNews.com initiated coverage on Omnicell in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $179.17.

Shares of OMCL opened at $114.90 on Tuesday. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of 77.11, a PEG ratio of 2.86 and a beta of 1.20. The business’s fifty day moving average price is $126.77 and its two-hundred day moving average price is $152.86. Omnicell has a 52 week low of $104.32 and a 52 week high of $187.29.

Omnicell (NASDAQ:OMCL – Get Rating) last announced its quarterly earnings data on Thursday, April 28th. The company reported $0.83 EPS for the quarter, beating the Zacks’ consensus estimate of $0.40 by $0.43. The firm had revenue of $319.00 million for the quarter, compared to analyst estimates of $313.98 million. Omnicell had a return on equity of 11.35% and a net margin of 6.00%. The business’s quarterly revenue was up 26.7% compared to the same quarter last year. During the same period last year, the company earned $0.62 EPS. On average, equities analysts forecast that Omnicell will post 2.38 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of OMCL. Swiss National Bank raised its stake in Omnicell by 0.5% during the 3rd quarter. Swiss National Bank now owns 95,400 shares of the company’s stock worth $14,160,000 after buying an additional 500 shares during the period. Congress Asset Management Co. MA raised its stake in Omnicell by 4.8% during the 3rd quarter. Congress Asset Management Co. MA now owns 68,453 shares of the company’s stock worth $10,160,000 after buying an additional 3,108 shares during the period. Synovus Financial Corp raised its stake in Omnicell by 3.4% during the 3rd quarter. Synovus Financial Corp now owns 15,235 shares of the company’s stock worth $2,259,000 after buying an additional 505 shares during the period. Pembroke Management LTD raised its stake in Omnicell by 0.8% during the 3rd quarter. Pembroke Management LTD now owns 155,048 shares of the company’s stock worth $23,014,000 after buying an additional 1,205 shares during the period. Finally, Mackenzie Financial Corp raised its stake in shares of Omnicell by 48.8% in the 3rd quarter. Mackenzie Financial Corp now owns 3,068 shares of the company’s stock valued at $455,000 after purchasing an additional 1,006 shares during the period.

About Omnicell (Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Articles